-
Active Trials
-
Phase 3
-
Phase 2
-
Phase 1
-
Results Pending
📊
Pipeline Summary
Expected Approvals
FDA Decisions 2 upcoming PDUFA dates
Datroway (datopotamab deruxtecan) First-line metastatic triple-negative breast cancer (TNBC) sBLA
Enhertu (trastuzumab deruxtecan) - post-neoadjuvant HER2-positive early breast cancer with residual invasive disease (DESTINY-Breast05) sBLA
Clinical Trials
Loading...